MedTrace Logo

USE THE SYSTEMIC METFORMIN IN MELASMA

NCT03475524 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-03

No results posted yet for this study

Summary

Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV radiation, pregnancy, and exogenous hormones (such as oral contraceptives,thyroid hormones, and hormone replacement therapy). Other factors implicated are phototoxic drugs, anticonvulsant medications,and the use of certain cosmetics. Types of melasma are epidermal, dermal and mixed according to location of melanin.

Conditions

  • Melasma

Interventions

DRUG

MetFORMIN 1000 Mg Oral Tablet

oral tablet 1ooomg systemic metformin will be given to group

DRUG

Placebos

oral placebos will be given to control beside trichloracetic acid peeling

DRUG

Trichloroacetic Acid Peeling

Trichloroacetic acid peeling to the three groups

DRUG

MetFORMIN 500 Mg Oral Tablet

oral tablet 500 mg

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03475524 on ClinicalTrials.gov